2024
Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
Bar N, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, De Champlain A, Gries K, Chen D, Li Q, Yeh T, Slaughter A, Lonardi C, Benachour N, Ghosh A, Deraedt W, Vogel M, Lendvai N, Patel N, Costa Filho O, Florendo E, Karlin L, Weisel K. Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial. Blood 2024, 144: 2002-2002. DOI: 10.1182/blood-2024-209232.Peer-Reviewed Original ResearchProgression-free survivalAnti-myeloma therapyLenalidomide-refractory multiple myelomaCilta-celMedian follow-upFollow-upMultiple myelomaStandard of careCiltacabtagene autoleucelProgressive diseaseMedian timeSOC armRefractory to lenalidomideYears of follow-upAnti-myeloma treatmentKaplan-Meier methodData cut-offCox proportional hazards modelsConfidence intervalsWorsening of symptomsRisk of deathProportional hazards modelFunctional impactEuropean Organization for ResearchMM patientsComparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Burnett H, Cost P, Schecter J, Lendvai N, Patel N, Ishida T, Er J, Harrison S, Lopez-Muñoz N. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison. Current Medical Research And Opinion 2024, 40: 1597-1603. PMID: 39129504, DOI: 10.1080/03007995.2024.2391112.Peer-Reviewed Original ResearchRelapsed/refractory multiple myelomaEfficacy of ciltacabtagene autoleucelIde-celProgression-free survivalCilta-celIdecabtagene vicleucelCiltacabtagene autoleucelMultiple myelomaTreated with 2Risk of disease progressionDistribution of prognostic factorsIndirect comparisonsRefractory multiple myelomaTreatment of patientsCox proportional hazards modelsMatching-adjusted indirect comparisonWeighted Cox proportional hazards modelsLogistic regression analysisProportional hazards modelCARTITUDE-1Partial responseTriple-classPrognostic factorsPatient-level dataClinical benefit
2023
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Cost P, Schecter J, Lendvai N, Patel N, Ishida T, Er J, Harrison S, Lopez-Muñoz N. Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison. Blood 2023, 142: 2141. DOI: 10.1182/blood-2023-182141.Peer-Reviewed Original ResearchIndividual patient-level dataMatching-adjusted indirect comparisonProgression-free survivalRefractory multiple myelomaCARTITUDE-1Overall response rateMultiple myelomaUnanchored matching-adjusted indirect comparisonIdecabtagene vicleucelHazard ratioCAR-TsKaplan-MeierComparative efficacyIndirect comparisonConfidence intervalsChimeric antigen receptor T-cell therapyB-cell maturation antigenCox proportional hazards modelGood partial responseTreatment of patientsT-cell therapyWeighted logistic regression analysisProportional hazards modelPatient-level dataLogistic regression analysis